UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CELL & GENE THERAPY

ABL

ABL logo

ABL

Cell & Gene TherapyUnited States
Visit WebsiteContact Company

About ABL

ABL specialises in the development and manufacture of advanced biological therapeutics, with a particular focus on gene therapies, vaccines, oncolytics and immunotherapies. Working exclusively with client programmes rather than proprietary pipelines, the company positions itself as a dedicated development partner for organisations tackling some of the most complex disease areas in modern medicine.

The company's manufacturing capabilities span virus manufacturing and process development, aseptic fill finish, and cell and virus banking. These services are supported by biologics and quality control testing, giving clients access to an integrated development pathway under a single provider. ABL also supplies ELISA kits as commercial products, reflecting a broader engagement with laboratory and analytical workflows.

Government partnering is listed as a distinct service category, indicating that ABL works with public-sector and defence-adjacent clients in addition to commercial biotechnology and pharmaceutical sponsors. This positions the company within the wider landscape of biodefence and public health preparedness, alongside conventional clinical-stage biologics work.

The organisation operates under the ABL, Inc. legal identity and maintains multiple locations, supporting projects across process development, manufacturing scale-up, and aseptic production. Its integrated service model is suited to sponsors requiring continuity across early development and late-stage manufacturing without transferring programmes between providers.

Further information is available at ablinc.com.

Areas of Expertise

Gene TherapyImmunotherapyVaccines

Services & Capabilities

Gene TherapyImmunotherapyVaccines
Similar Companies

More in Cell & Gene Therapy

R

RSSL

RSSL (Reading Scientific Services) operates across two major industry verticals, providing contract laboratory and scientific services to clients in life sciences and pharmaceuticals as well as food and consumer goods. Based in Reading, UK, the organisation positions itself as an outsourced testing and innovation partner covering everything from early research and discovery through to manufacturing, commercialisation, and regulatory compliance. Within the pharmaceutical and life science sector, RSSL offers testing across a broad range of molecule and product types, including biologics, cell and gene therapy, consumer healthcare, small molecule pharmaceuticals, vaccines, veterinary medicine, and specialised nutritional products. Services are organised by development phase, allowing clients to engage at preclinical stages, through clinical development, and into commercial-scale manufacturing. Capabilities span pharmacopoeial testing, ICH stability studies, contamination and impurity analysis, microbiology testing, and a rapid mycoplasma screening and detection service, which the company describes as fast, compliant, and sensitive. A priority response service is also available for time-critical projects. RSSL maintains an Innovation Hub and a dedicated services directory spanning techniques and methods to support product development across its client base. The food and consumer goods division extends these analytical capabilities into food and beverages, ingredients, consumer goods, food service, specialised nutrition, nutraceuticals, and dietary supplements. A recently announced dedicated nutritional testing service, supported by a £1.2 million investment, reflects continued capital commitment to expanding laboratory capacity in this area. Further information is available at rssl.com.

View profile
V

Vaccitech

Antigen-specific immunotherapy is the clinical focus of Barinthus Biotherapeutics plc (formerly Vaccitech), a clinical-stage biopharmaceutical company dedicated to guiding T cells and antibodies to overcome autoimmunity and inflammatory disease. The company operates at the research and development frontier of immunology and inflammatory (I&I) indications, building on scientific foundations laid by academic institutions of international standing. Barinthus Bio emerged from the 2021 merger of Vaccitech, Plc, an Oxford University spinout, and Avidea Technologies, Inc., a spinout of the National Institutes of Health (NIH) and Johns Hopkins University. The combination united two complementary immunotherapeutics platforms and created a company with a broader base of T cell-directed therapeutic expertise than either predecessor held independently. The company's pipeline centres on autoimmunity, with its proprietary SNAP-TI technology supporting the development of tolerance immunotherapies designed to address the underlying drivers of inflammatory disease rather than managing symptoms alone. Barinthus Bio describes its approach as guiding the immune system to cure disease, a distinction it draws between its antigen-specific methodology and broader immunosuppressive strategies common in the I&I space. Headquartered in the United Kingdom, the company is listed and engages institutional investors through structured governance and regular news and filings activity. Its scientific founders come from leading research institutions, anchoring its discovery capabilities in a heritage of cutting-edge immunological innovation. Further information is available at vaccitech.co.uk.

View profile
A

Akron Biotech

Trusted by the cell and gene therapy sector since 2006, Akron Biotech supplies the ancillary materials that underpin advanced therapeutic manufacturing. Operating under the Akron Bio brand, the company occupies a specialised position in the biotech supply chain, providing the raw materials and contract services that research teams and commercial manufacturers depend on at every stage of development and scale-up. The product portfolio centres on three core categories: cytokines and growth factors, human plasma derived products, and media and media supplements. These materials are critical inputs for cell expansion, gene vector production, and the broader biomanufacturing workflows associated with advanced therapies. Alongside its catalogue offering, Akron Biotech runs dedicated manufacturing services covering proteins, media and buffers, and transfection and transduction reagents, giving clients a single source for both off-the-shelf supply and custom-manufactured components. Quality assurance is presented as a defining characteristic of the business. The company maintains regulatory support documentation and certificates for its materials, reflecting the compliance requirements of partners working in regulated therapeutic development environments. A knowledge centre comprising published posters, publications, and event resources further supports the scientific community using its products. Partnerships and collaborations form part of the company's stated commercial model, positioning Akron Biotech as an integrated supplier rather than a transactional vendor. Its leadership and newsroom functions suggest an active presence in the cell and gene therapy market rather than a passive catalogue role. Further information is available at akronbiotech.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy